Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14085)	2/2/1998 8:57:00 PM
From: celeryroot.com	Read Replies (2) \| Respond to of 32384

Henry, it is also fueled by the fact that some of these large pharms have some major patents running out shortly

To: Henry Niman who wrote (14085)	2/2/1998 10:41:00 PM
From: Sunny Jim	Read Replies (4) \| Respond to of 32384

<today's merger mania was being fueled for a large R&D requirement, but they compared big pharma valuations to Biotechs. MRK's market cap is $140 Billion and they spend $1.5 Billion on R&D. In contrast, all Biotechs combined had a market cap of $85 Billion with $5 Billion spent on R&D.> This is an interesting way to look at it. However, one major problem is boitechs have zip sales and marketing infrastructure, which is largely what turns the R&D into revenue. If biotechs are a great bargain, why aren't the big pharmas buying them? Comments?